#USA #NASDAQ #Wexford #Coeptis Therapeutics #Reverse Stock Split

Coeptis Therapeutics Implements Reverse Stock Split

Coeptis Therapeutics Holdings, Inc., renowned for its innovative work in biopharmaceuticals, recently disclosed a significant corporate action: a 1-for-20 reverse stock split of its outstanding common shares. This decision, sanctioned by both the company’s board of directors and the majority of its shareholders, is aimed at ensuring compliance with the Nasdaq Capital Market's minimum bid price rule, which requires stocks to maintain a minimum bid price of $1.00 per share. The execution of this reverse split is slated for December 31, 2024, marking a pivotal moment in the company’s strategy to strengthen its market position.

Background on Coeptis Therapeutics

Based in Wexford, Pennsylvania, Coeptis is at the forefront of developing advanced cell therapy solutions targeting a range of conditions, including cancer, autoimmune disorders, and infections. Their innovative approach aims to fundamentally alter conventional treatment methodologies while improving patient outcomes. The company’s portfolio features notable assets, such as those licensed from Deverra Therapeutics, which encompasses pioneering immunotherapy platforms and natural killer cell therapy technologies.

Details of the Reverse Stock Split

The reverse stock split, which will convert every 20 shares into a single share, is designed to enhance the stock's trading price without affecting the overall holdings of existing shareholders — barring minor adjustments for any fractional shares that result from the change. This strategic move is not only about compliance but also reflects a broader goal of positioning Coeptis favorably for future growth and market viability. In the event of fractional shares, these will be rounded up to ensure no shareholder is negatively impacted.

The decision to proceed with the reverse split was solidified during the company's Annual Stockholder's Meeting on December 18, 2024, where shareholders expressed their support for this crucial initiative.

Implications for Shareholders and the Market

For shareholders, this split represents an important step towards stabilizing the stock price and enhancing the overall market perception of Coeptis. The company aims to create a more attractive investment proposition while upholding its commitment to transparency and stakeholder value. Notably, Continental Stock Transfer will be overseeing the logistics of this change, providing instructions for existing stockholders on how to manage their new shares effectively.

Looking ahead, Coeptis Therapeutics remains focused on its growth trajectory and the expansion of its cutting-edge cell therapy technologies. With its diverse portfolio and strategic initiatives, the company is well-positioned to navigate the complexities of the biopharmaceutical landscape. The reverse split is not merely a reaction to market constraints but rather a step towards reinforcing the fundamental strengths of the company.

Conclusion

The upcoming reverse stock split demonstrates Coeptis Therapeutics' proactive approach to market challenges while emphasizing its dedication to developing innovative solutions in biopharmaceuticals. As they navigate this transformative period, the company is poised to continue its pursuit of excellence in therapeutic advancements, ultimately benefiting its patients and investors alike. With renewed focus following the split, shareholders can anticipate further developments from this pioneering biotech firm.

For more information on Coeptis Therapeutics and its innovative therapies, you can visit their official site at Coeptis Therapeutics.